Korro Bio Reports $18.9 Million Net Loss in Q2 2026, Sees Decrease in Operating Expenses

Korro Bio, Inc. reported its financial results for the second quarter of 2026, revealing a net loss of $18.9 million, a decrease from a net loss of $25.8 million in the same period last year. For the six months ended June 30, 2026, the company recorded a net loss of $38.5 million, down from $49.2 million in the prior year. The company did not generate any revenue from product sales during this period, and collaboration revenue dropped significantly from $4.0 million in the first half of 2025 to zero in 2026, primarily due to a 12-month pause in its collaboration with Novo Nordisk.

Operating expenses for the second quarter of 2026 totaled $20.1 million, a reduction from $28.7 million in the same quarter of 2025. This decline was attributed to lower research and development costs, which fell to $13.6 million from $20.1 million year-over-year, largely due to the termination of the Phase 1/2a REWRITE clinical trial for KRRO-110. General and administrative expenses also decreased to $6.5 million from $7.3 million, reflecting cost-cutting measures following workforce reductions implemented in 2025.

Korro Bio's total assets increased to $163.4 million as of June 30, 2026, compared to $113.5 million at the end of 2025. This growth was driven by a rise in cash and cash equivalents, which reached $24.9 million, alongside an increase in short-term marketable securities from $53.3 million to $90.1 million. The company’s accumulated deficit stood at $422.4 million, highlighting the ongoing financial challenges it faces as it continues to invest heavily in research and development.

Strategically, Korro Bio is advancing its OPERA platform, which focuses on RNA-editing oligonucleotides (REOs) for treating genetic diseases. The company is preparing to initiate a first-in-human trial for KRRO-121, a potential treatment for hyperammonemia, in the second half of 2026. Additionally, KRRO-111, aimed at treating alpha-1 antitrypsin deficiency, has shown promising preclinical results. The company plans to nominate a third development candidate later this year, indicating a commitment to expanding its pipeline despite the financial losses.

Looking ahead, Korro Bio anticipates continued operating losses and negative cash flows as it progresses through clinical development and seeks regulatory approvals. The company has approximately $137.9 million in cash, cash equivalents, and marketable securities, which it expects will fund operations into the second half of 2028. However, it acknowledges the need for additional funding to support its ongoing research and development efforts, emphasizing the uncertainty surrounding its future financial stability and operational viability.